Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
2003
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Parenteral Anticoagulants
2008
Parenteral Anticoagulants
2012 Standout
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
Mechanisms of Thrombus Formation
2008 Standout
Utilisation and Safety of Low Molecular Weight Heparins
2003
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel
2007
Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases
2008 StandoutNobel
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
The Pharmacokinetics of Fondaparinux Sodium in Healthy Volunteers
2002
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Is Impaired Renal Function a Contraindication to the Use of Low-Molecular-Weight Heparin?
2002
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
2003
The Future of Antiplatelet Therapy: Optimizing Management in Patients with Acute Coronary Syndrome
2000
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
New Antithrombotic Drugs
2012
Platelet-Active Drugs
1998
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
Chest radiography for the diagnosis of acute aortic syndrome
2004
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery<subtitle>A Multicenter, Randomized, Placebo-Controlled, Double-blind Study</subtitle>
2003
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
2002 Standout
P2Y12Receptors in Spinal Microglia Are Required for Neuropathic Pain after Peripheral Nerve Injury
2008
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
Individual variations of platelet inhibition after loading doses of clopidogrel
2002 StandoutNobel
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Once versus twice daily LMWH for the initial treatment of venous thromboembolism
2002
The P2Y1 receptor, necessary but not sufficient to support full ADP‐induced platelet aggregation, is not the target of the drug clopidogrel
1998
Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation
2002
Antithrombotic Therapy for VTE Disease
2012 Standout
Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel
2008
Platelet Activation and Atherothrombosis
2007 Standout
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
2013 Standout
Antiplatelet Drugs
2012
Structure and Stereochemistry of the Active Metabolite of Clopidogrel
2002
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
2005
Pharmacology of Antiplatelet Agents
2013
Factor V Leiden and Morbid Obesity in Fatal Postoperative Pulmonary Embolism
2000
Polymer Therapeutics: Concepts and Applications
2006
Heparin and Low-Molecular-Weight Heparin
2004
2-Amino-1,3,4-thiadiazoles in the 7-hydroxy-N-neopentyl spiropiperidine indolinyl series as potent P2Y1 receptor antagonists
2014
Antiplatelet Drugs
2008
P2Y12, a New Platelet ADP Receptor, Target of Clopidogrel
2001
Prevention of Venous Thromboembolism
2004 Standout
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
2007
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
From carbohydrate leads to glycomimetic drugs
2009
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
2005
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Venous thromboembolism and fractured neck of femur
2005
Fondaparinux Sodium Is Not Metabolised in Mammalian Liver Fractions and Does Not Inhibit Cytochrome P450-Mediated Metabolism of Concomitant Drugs
2002
Fondaparinux Sodium Mechanism of Action
2002
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis
2001
The P2Y12 receptor regulates microglial activation by extracellular nucleotides
2006 StandoutNobel
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
2001 Standout
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Identification of the platelet ADP receptor targeted by antithrombotic drugs
2001 StandoutNatureNobel
Platelet-Active Drugs
2001
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
New Antithrombotic Agents
1998
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
2004
Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting
2000
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss
2005 Standout
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006
Clopidogrel Versus Dipyridamole in Addition to Aspirin in Reducing Embolization Detected With Ambulatory Transcranial Doppler
2011
Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitro
2002
Elderly Patients Treated with Tinzaparin (Innohep®) Administered once Daily (175 Anti-Xa IU/kg): Anti-Xa and Anti-IIa Activities over 10 Days
2000
Identification and Biological Activity of the Active Metabolite of Clopidogrel
2000
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
2006
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Catalytic Enantioselective Conversion of Epoxides to Thiiranes
2016 StandoutNobel
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
Highly Selective Copper-Catalyzed Ring Expansion of Vinyl Thiiranes: Application to Synthesis of Biotin and the Heterocyclic Core of Plavix
2007
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel
2005
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
2005
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Stereoselective Enzymatic Synthesis of Heteroatom-Substituted Cyclopropanes
2018 StandoutNobel
Ultrastructural Studies of Platelet Aggregates From Human Subjects Receiving Clopidogrel and From a Patient With an Inherited Defect of an ADP-Dependent Pathway of Platelet Activation
1996
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function
2007
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children
2008
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
2000
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Diastereoselective Allylation of Carbonyl Compounds and Imines: Application to the Synthesis of Natural Products
2013 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules
2016
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
The Antiplatelet Effects of Ticlopidine and Clopidogrel
1998
Managing anticoagulant and antiplatelet drugs in patients who are receiving neuraxial anesthesia and epidural analgesia: a practical guide for clinicians
2006
The Antiaggregating and Antithrombotic Activity of Clopidogrel Is Potentiated by Aspirin in Several Experimental Models in the Rabbit
1998
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
2004 Standout
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
Synthesis and Applications of tert-Butanesulfinamide
2010
Polymere Therapeutika: Konzepte und Anwendungen
2006
Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?
2005
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients
2009
Physiology of Microglia
2011 Standout
Works of J Necciari being referenced
The Synthetic Pentasaccharide Fondaparinux: First in the Class of Antithrombotic Agents that Selectively Inhibit Coagulation Factor Xa
2002
Pharmacodynamics and Tolerance of Two Nadroparin Formulations (10,250 and 20,500 Anti Xa IU·ml-1) Delivered for 10 Days at Therapeutic Dose
1998
Pharmacokinetics of clopidogrel.
1999
Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices.
2003
Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction.
1999
Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent
1993
Current trends in the use of heparins in thromboprophylaxis.
1999
Clopidogrel bioavailability: absence of influence of food or antacids.
1999
Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man
1995
Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin)
1998
SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent
1997
Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis.
1999